US Stock MarketDetailed Quotes

LRMR Larimar Therapeutics

Watchlist
  • 4.180
  • +0.170+4.24%
Close Jan 3 16:00 ET
  • 4.180
  • 0.0000.00%
Post 20:01 ET
266.71MMarket Cap-3.63P/E (TTM)

Larimar Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Larimar Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 6 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
--2024/Q30.000 / 0.000--
--2024/Q20.000 / 0.000--
--2024/Q10.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
--2024/Q30.000 / 0.000--
--2024/Q20.000 / 0.000--
--2024/Q10.000 / 0.000--

Unlock Free Earnings Estimates

Larimar Therapeutics Earnings Reports

  • Larimar Therapeutics | 10-Q: Q3 2024 Earnings Report

    Oct 30, 2024 17:07 ET

  • Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

    Oct 30, 2024 07:07 ET

  • Larimar Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 8, 2024 14:44 ET

  • Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results

    Aug 7, 2024 07:06 ET

    • Read more

    Trending US Stocks
    Best Growth Stocks Best Growth Stocks

    Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

    Symbol Mini Chart % Chg
    DexCom
    DXCM
    +3.27%
    Collegium Pharmaceutical
    COLL
    +3.07%
    Lantheus
    LNTH
    +2.71%
    Cars.com
    CARS
    +1.72%
    YETI Holdings
    YETI
    +1.60%

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Jan 3, 2025

    Strong Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data